Recent longitudinal studies provide strong support for researchers to determine the role of silicon in aging. It is accepted in the literature that the concentration of silicon continues to decline throughout your life; however, supplementing with forms of silicon like LIVING SILICA(r) that have high bioavailability are thought to help maintain skin thickness and elasticity. Much research has been directed to how silicon supports the synthesis of elastin and collagen. Therefore, silicon has been utilized as part of an "anti-aging" program, as well as during the maintenance phase of a bone health program. Clinical studies conducted regarding bone health show the positive correlation of silicon intake to an increase in the bone mineral density (BMD) of the femoral neck. In addition to bone health, clinical studies have been undertaken to examine the interactions between silicon, hyaluronic acid and proteoglycans to help maintain the viscosity of synovial fluid. The results of these studies demonstrate that silicon functions as a mineral that modulates the mineral to collagen ratio of the bone matrix and is necessary for bone integrity. The EFSA's opinion on silicon in 2011 was entirely based on the differing types of supplements available then. It appears that the medical community has grown increasingly optimistic regarding the possible usefulness of silicon for improving skin and joint health. We know the main reasons for the lack of benefit in previous studies were primarily related to the absence of a bioavailable form of silicon, as the stabilized forms of silicon permit effective absorption into the systemic circulation by the human gut, thereby allowing for the biological benefits to the connective tissue to be clinically evident. Current studies support and verify that silicon has been effective within a context of "preventative aging." Although some may state that the research is still evolving regarding silicon's role compared to other minerals like calcium and zinc, the current body of research is convincing for silicon's role in supporting skin elasticity and joint comfort. No longer are the studies claiming the body of evidence supporting silicon as being "limited" - instead, the body of research is becoming increasingly specific as to the chemical or elemental characteristics and the bioavailability of a stabilized form of silicon having relevance to connective tissue biological functioning.
There is a growing trend for dermatological and musculoskeletal health from recent studies surrounding highly bioavailable monomethylsilanetriol (MMST) formulations, such as found in LIVING SILICA(r). Recent evidence shows that organic silicon acts as a biological cross-linking agent for glycosaminoglycans and collagen, which are both critical components for maintaining the structural integrity of the dermis and improving tensile strength of hair. The studies also support that the ability of the specific molecular form of silicon to be absorbed and utilized by targeted tissues is the primary factor that determines its effectiveness. Clinical trials have provided measurable evidence of a relationship between silicon and connective tissue. Silicon is abundant in areas of bone where there is active calcification. Since silicon stimulates osteoblast activity and inhibits the resorption of osteoclasts, it is likely that silicon promotes bone health. With respect to joints, clinical trials demonstrate that silicon assists with stabilizing the extracellular matrix, thereby reducing cartilage breakdown. Thanks in large part to the "biological glue" of the body, it is now recommended that many patients use silicon to help their joints and maintain healthy bones. The current medical viewpoint regarding silicon has changed since the EFSA 2011 Opinion. The EFSA did not presently determine a relationship of "cause and effect" due to conflicting scientific data on multiple low-bioavailability silicon forms. Today, it is widely accepted that not all silicones are created equal. There are distinct differences between silicates with low levels of bioavailability and organic silicon with high levels of bioavailability. The 2011 EFSA Opinion provides a conservative baseline, but many practitioners believe that silicon is an essential trace element for collagen-dense tissues, provided that the delivery system is designed to allow for cellular uptake. Recent studies have generally supported the findings of previous studies concerning the benefits of using silicon for skin elasticity and bone mineral density. Additionally, while the data supporting hair strength is not as extensive, it is becoming more apparent that the repeated finding that silicon promotes the action of the enzyme prolyl-hydroxylase is well documented.
Founder & Medical Director at New York Cosmetic Skin & Laser Surgery Center
Answered a month ago
Patients ask me about LIVING SILICA. I have not seen a peer reviewed 2025 randomized trial on that branded formula for skin, hair, joints, or bone. Silicon has a plausible role in connective tissue, but supplements need clinical endpoints. If I suggest anything oral, I want blinded data, clear dosing, and safety. I found only CosmoDerma 84 day study tracked 22 women ages 40 to 66 taking 14 mg silicon daily as Mesoporosil. They reported gradual improvements in firmness, hydration, wrinkles, and elasticity. No adverse events were reported. Overall acceptance was 55.8% at day 28 and 61.4% at day 84. This was small and subjective. EFSA's 2011 opinion still applies: silicon health claims for collagen, skin, hair, joints, and bone remain unproven.